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Intravenous renal cell transplantation with SAA1-positive cells prevents the
progression of chronic renal failure in rats with ischemic-diabetic nephropa-
thy. Am J Physiol Renal Physiol 305: F1804–F1812, 2013. First published
October 16, 2013; doi:10.1152/ajprenal.00097.2013.—Diabetic nephropa-
thy, the most common cause of progressive chronic renal failure and
end-stage renal disease, has now reached global proportions. The only
means to rescue diabetic patients on dialysis is renal transplantation,
a very effective therapy but severely limited by the availability of
donor kidneys. Hence, we tested the role of intravenous renal cell
transplantation (IRCT) on obese/diabetic Zucker/SHHF F1 hybrid
(ZS) female rats with severe ischemic and diabetic nephropathy.
Renal ischemia was produced by bilateral renal clamping of the renal
arteries at 10 wk of age, and IRCT with genetically modified normal
ZS male tubular cells was given intravenously at 15 and 20 wk of age.
Rats were euthanized at 34 wk of age. IRCT with cells expressing
serum amyloid A had strong and long-lasting beneficial effects on
renal function and structure, including tubules and glomeruli. How-
ever, donor cells were found engrafted only in renal tubules 14 wk
after the second infusion. The results indicate that IRCT with serum
amyloid A-positive cells is effective in preventing the progression of
chronic kidney disease in rats with diabetic and ischemic nephropathy.
chronic renal failure; diabetic nephropathies; organ regeneration;
serum amyloid A
PROGRESSIVE CHRONIC KIDNEY DISEASE (CKD) transitions to end-
stage renal disease (ESRD) after reaching an undefined tipping
point. This critical transition and the overall pathophysiology
that drives the progression of CKD to that point are not well
understood (31). Progressive CKD remains untreatable, and its
conversion to ESRD is generally unstoppable. The most com-
mon cause of the progression of CKD to ESRD is diabetic
nephropathy (DN) (13), a massive global problem with a
prevalence of antecedent microalbuminuria and macroalbu-
minuria of 49% and impaired renal function of 22% in type 2
diabetics who had been unaware of having nephropathy (23).
Our work with DN has revealed that acute renal injury, com-
mon in diabetic patients, is a major contributor to progressive
CKD (13), a finding supported by epidemiological data (10,
28). In other words, very large numbers of diabetics are at high
risk of progressive CKD, and many of those face the prospect
of an irrevocable renal decline to ESRD. For some, renal
transplantation is an effective way to treat ESRD; however,
most ESRD patients encounter difficult barriers to reach trans-
plantation: 20% are placed on waiting lists for kidney trans-
plantation, and, after several years, only 10% eventually re-
ceive a kidney (33). The majority of ESRD patients remain on
dialysis, and most patients ultimately succumb to painful
complications.
One promising approach to CKD-ESRD is regenerative
nephrology, and attempts have been made to restore renal
function in animal models with stem cells, a logical sequel to
reports (11, 29) demonstrating that endogenous stem cells are
mobilized to the injured kidney, although the latter view was
subsequently refuted (2, 21). Stem cell transplantation has been
performed with bone marrow-derived mesenchymal stem cells
(2), adipose tissue-derived stem cells (4), and embryonic stem
cells (7). Unfortunately, renal engraftment of donor stem cells,
or, for that matter, donor stem cell differentiation into renal
cells, has not been verified in DN to our knowledge. We
devised a completely different strategy and used adult renal
cell transplantation in DN with CKD. We accomplished long-
term kidney cell engraftment and successful renal regeneration
with auto-transplants of adult primary kidneys cells repro-
grammed to express the tubulogenic protein serum amyloid A1
(SAA) (19). We now report that allogeneic rat adult kidney
cells, given intravenously, prevent long-standing progressive
CKD caused by ischemia and DN in obese rats. The diabetic/
ischemic model was designed to mimic DN in humans (12, 14),
in which overt and/or subclinical episodes of acute kidney
injury from ischemia and the resulting inflammation can con-
tribute to the progression of CKD (13, 28, 32). The two
separate doses of reprogrammed renal epithelial cells were
given after the renal disease was well established, and en-
grafted donor cells were identified in recipient kidneys 14 wk
after the last dose of cells. We also convey here that cell
transplantation with SAA-expressing tubular cells restored
damaged microvascular networks, assured the structural integ-
rity of glomeruli and tubules, and prevented glomerular and
interstitial fibrosis, the main pathological determinants of the
progression of CKD in DN (5). We propose that intravenous
renal cell transplantation (IRCT) is safe and very effective in
preventing the progression of CKD in rats with advanced
ischemic DN.
METHODS
Primary renal tubular cells. Primary renal tubular cells were
obtained from lean, age-matched male Zucker/SHHF F1 hybrid (ZS)
rats (Charles River, Wilmington, MA), and renal cells from one lean
rat were equally distributed to four obese rats, one in each of the four
groups. Lean rats were euthanized by removal of both kidneys under
general anesthesia. The kidney cortices were minced with scissors in
S1 medium (described below) and digested with collagenase type IV
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(6 mg/dl, Worthington, Lakewood, NJ) at 37°C in 38% O2 and 5%
CO2 for 50 min. Renal tubules were then separated by a Percoll
gradient (19), divided into two sets, resuspended in 300 l of trans-
fection buffer (containing 20 mM HEPES, 142 mM KCl, 6 mM
dextrose, 0.7 mM Na2HPO4, 5 mM MgATP, and 10 M EGTA), and
transfected by electroporation (40 V  12 ms  500 ms  6 pulses).
The isolated tubules were a mix of different tubule segments: approx-
imately 25% proximal (positive for organic anion transporter 1), 20%
thick ascending limb (positive for Tamm Horsfall protein), 15%
collecting tubule (positive for aquaporin 2), and 5% distal convoluted
tubule (positive for thiazide-sensitive cotransporter) (19). The remain-
ing cells were not identified by these markers (19). Control or
SAA1-negative (group A) tubules were cotransfected with empty
vector pcDNA3.1 (30 g), pAcGFP1-C1 [15 g, green fluorescent
protein (GFP) is the cytosolic label used to track cells in vivo,
Clontech, Mountain View, CA], and pCruz HASIRT1 (15 g, Add-
gene), which expresses sirtuin 1 (SIRT1), a NAD-dependent
deacetylase that may have a role in resistance to cellular stress and,
thus, has been used in previous transplant protocols (19). For SAA1-
positive cells (group B), pcDNA3.1 was replaced with pcDNA3.1-
SAA1 plasmid (30 g), which was manufactured and sequenced in
our laboratory; its construction has been previously reported (15, 19).
Transfection efficiencies were 70% (19).
Cotransfected tubules were cultured in S1 medium. Two liters of
S1 medium contained 10.7 g F-12 HAM, 8.32 g DMEM, 0.29 g
L-glutamine, 4.78 g HEPES, 1.7 g sodium selenite, 0.11 g sodium
pyruvate and 3.2 ml phenol red, and pH was adjusted to 7.4 with
sodium bicarbonate (Sigma). S1 medium was supplemented with 200
ng/ml hepatocyte growth factor and 400 ng/ml epidermal growth
factor (R&D Systems, Minneapolis, MN). The medium also contained
100 g/ml hydrocortisone, 35 g/ml insulin, 32 g/ml transferrin,
and 42 ng/ml sodium selenite (Sigma), with 20% FCS. G-418 (75
g/ml) was added after 48 h of culture for selection. In preparation for
transplantation, male renal tubular cells were lightly trypsynized after
7–8 days in culture, washed in PBS, and injected intravenously in the
tail vein of obese, diabetic female rats at 15 wk of age and again at 20
wk of age.
Animal protocols. All experiments were conducted in conformity
with the “Guiding Principles for Research Involving Animals and
Human Beings,” and approved by the Institutional Care and Use
Committee. Female ZS rats (Charles River) were acquired at 8 wk of
age and fed Purina diet 5008 with 27% protein, 17% animal fat, and
56% carbohydrate. Weights, sera, and urine were collected biweekly,
and chemistries were measured by the Indianapolis Veterans Affairs
clinical laboratory. Urine protein was measured via ELISA according
to the manufacturer’s protocol (Exocell, Philadelphia, PA). At 10 wk
of age, rats were anesthetized with inhaled isofluorane (0.5–1%) and
placed on a homeothermic table to maintain the body core temperature
at37°C. In two groups of rats, both renal pedicles were occluded for
25 min with microaneurysm clamps as previously described (18). In
two other groups, sham surgery consisted of the identical surgical
procedure except that the renal pedicles were not clamped. Two
groups of rats were later infused with donor cells: one sham-operated
(sham) group (SA group; n  6) received group A cells and another
sham group (SB group; n  6) received group B cells (see above).
One ischemic group (IA group; n 9) received group A cells, and the
other ischemic group (IB group; n  9) received group B cells (see
above). The cell dose (106 cells/rat) was based on a previous study
(19). A second infusion was administered given the chronicity of the
injury.
Histology and immunohistochemistry. Kidney sections were fixed
in 3.8% paraformaldehyde and embedded in paraffin, and 5-m
sections obtained for Masson’s trichrome to stain connective tissue,
periodic acid-Schiff (PAS) to image cellular morphology, and Leder’s
stain to visualize neutrophils. Areas of glomerular and peritubular
fibrosis were quantified using Metamorph imaging-processing soft-
ware (Sunnyvale, CA) and expressed as fractional areas per 200
microscope field, covering all available surfaces in all coded kidneys.
Atrophic tubules were counted in blinded PAS-stained sections. Renal
neutrophils were also counted in the kidney sections. Additional
kidney sections were used to visualize the microvasculature by im-
munohistochemistry using an anti-Von Willebrand factor antibody
(Autostainer procedure by Dako, Carpinteria, CA) (26). The micro-
vasculature density was estimated from the pixel density representa-
tive of von Willebrand factor (Metamorph software). Immunohisto-
chemistry for proliferating cell nuclear antigen (PCNA) was per-
formed using anti-PCNA (sc-7907, Santa Cruz Biotechnology, Santa
Cruz, CA) and Texas red secondary antibody. Quantification of
PCNA-positive and apoptotic cells [determined by characteristic nu-
clear morphology of 4=,6-diamidino-2-phenylindole (DAPI)-labeled
nuclei (14, 16)] was performed on blinded sections. Kidneys fixed in
4% paraformaldehyde were also sectioned into 100-m slices with a
Vibratome (Vibratome, St. Louis, MO). Sections were immersed in
PBS with 0.2% Triton X-100 for 5 min, washed three times with PBS,
blocked for 15 min in PBS with 0.2% BSA, incubated with the rabbit
primary anti-SAA antibody (16, 19) in PBS for 30 min at 37°C, and
then washed in PBS. Fluorescent secondary antibody, Texas red-
conjugated donkey anti-rabbit (catalog no. 111-075-045, Jackson
ImmunoResearch, West Grove, PA), was then applied for 30 min at
37°C followed by a wash. Nuclei were stained with the nuclear dye
DAPI (Molecular Probes, Eugene, OR). Renal images of visualized
intrinsic GFP and Texas red-labeled SAA were collected with a Leica
DMI 3000B fluorescence microscope.
Fluorescent in situ hybridization of the Y chromosome. Fluorescent
in situ hybridization (FISH) was used to localize the Y chromosome
in female kidneys months after IRCT with male renal cells as
previously reported (19). In brief, at euthanization, recipient kidneys
were immediately fixed in 10% neutral formalin, embedded in paraf-
fin, cut along the sagittal main axis into 5-m sections, and affixed to
glass slides. Slides were sequentially placed in xylene for 15 min
twice, 100% ethanol for 5 min twice, boiling saline-sodium citrate
(SSC) buffer for 10 min, cooled down to room temperature, and
washed with distilled water. Sections were then digested with 0.4%
pepsin and 0.9% NaCl (pH 1.5) at 37°C for 50 min, washed with
distilled water, immersed in 2 SSC for 10 min twice, and air dried.
FISH was conducted with the fluorescent-labeled rat Y chromosome
probe (Rat Idetet Chr Y Paint probe red, ID 556, catalog no.
IDRR1070-0111, excitation: 548 nm and emission: 573 nm, ID Labs
Biotechnology, London, ON, Canada) diluted 1:10, and 5 l were
applied to the prepared kidney section. The slide was covered, and
kidney DNA and the probe were denatured at 69°C for 2 min and then
hybridized overnight at 40°C. The slide was then uncovered and
placed in warmed 0.4 SSC with 0.3% Nonidet P-40 (70°C for 2
min). The slide was incubated in 2 SSC solution at room tempera-
ture for 1 min. The section was then washed with distilled water, air
dried, mounted with DAPI, covered, and imaged on a fluorescent
microscope.
Renal SAA1 mRNA. RT-PCR was used for the amplification of
SAA1 mRNA in recipient kidneys at euthanization. RNA was ex-
tracted from homogenized renal cortices in lysis buffer, isolated with
a purification kit as recommended by vendor (catalog no. 12183-555,
Invitrogen), and cleaned with an RNeasy Mini kit as recommended by
vendor (catalog no. 74104, Qiagen, Valencia, CA). For RT-PCR, 2 g
of total RNA were used to synthesize cDNA with an AffinityScript
QPCR cDNA Synthesis Kit as recommended by the vendor (catalog
no. 600559, Aligent Technologies, Santa Clara, CA). The murine
SAA1 mRNA was amplified using the following primers (15): for-
ward 1, 5=-CGCCACCATGGAGGGTTTTTTTCATTTGTTCAC-3=;
forward 2, 5=-TACAGGCTAGCGCCACCATGGAGGGTTT-3=; and
reverse 1/2, 5=-TCAGGTGGATCCCTCAGTATTTGTCAG-3=.
Twenty-five microliters of PCR master solution contained 1 PCR
buffer, 0.25 mM dNTP, 0.25 M primers, and 0.25 l Herculase II
DNA polymerase (catalog no. 600675-51, Aligent). cDNA (0.5 l)
was added to each tube, and PCR amplification was conducted: 95°C
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at 5 min for 1 cycle, 95°C for 20 s, 57.5°C for 30 s, and 72°C for 30
s for 40 cycles, and then at 72°C for 7 min for 1 cycle (PCR System
2400, Perkin-Elmer, San Jose, CA). PCR products were separated on
a 2.5% agarose gel.
Identification of DNA encoding the male sex-determining region on
chromosome Y localized in female kidneys. DNA was extracted from
the recipient kidneys with the Wizard Genomic DNA Purification Kit
as indicated by the manufacturer (Promega, Madison, WI). Specific
sex-determining region on chromosome Y (SRY) DNA was then
amplified from extracted kidney DNA using the following primers
(25): forward 1 5=-AAGCGCCCCATGAATGC-3=; and reverse 1/2,
5=-AGCCAACTTGCGCCTCTCT-3=.
Twenty-five microliters of PCR master solution contained 1 PCR
buffer, 0.25 mM dNTP, 0.25 M primers, and 0.25 l Herculase II
DNA polymerase (catalog no. 600675-51, Aligent). Kidney DNA (0.5
l) was added to each tube, and PCR amplification was conducted:
95°C for 5 min for 1 cycle, 95°C for 20 s, 57.5°C for 30 s, and 72°C
for 20 s for 35 cycles, and then at 72°C for 7 min for 1 cycle (PCR
System 2400, Perkin-Elmer). PCR products were separated on a 2.5%
agarose gel.
Statistics. Data are expressed as means SE. ANOVA was used to
determine if differences among mean values reached statistical sig-
nificance. Student’s t-test (two tailed, two sample, unequal variance)
was used for comparisons between groups (GraphPad Prism, La Jolla,
CA). Tukey’s test was used to correct for multiple comparisons. The
null hypothesis was rejected at P  0.05.
RESULTS
There were four major groups of female obese diabetic rats:
two groups were subjected to sham surgery and two other
groups were subjected to bilateral renal ischemia at 10 wk of
age. Rats were cell transplanted at 15 and 20 wk of age, and all
were euthanized at 34 wk of age. Sham rats were twice infused
with SAA negative (group A) cells (control cells, SA group;
n  6) or with SAA-expressing (group B) cells (repro-
grammed, SB group; n  6). Rats subjected to bilateral renal
ischemia were also twice infused with SAA-negative cells
(control cells, IA group; n  9) or with SAA-expressing
(group B) cells (reprogrammed, IB group; n  9). Two rats
died in the group of nine rats with added renal ischemia and
transplanted with SAA-negative cells; the rats died 2 and 8 wk
after the second cell transplant. Animal weights and serum
glucose values were comparable in all four diabetic groups with
no statistically significances observed over the course of the study.
(Mean blood glucose levels in the four diabetic groups were
significantly higher than those in lean rats; Table 1.)
Urinary protein excretion was higher in rats from the sham
and ischemic groups transplanted with control SAA-negative
cells than in the two other respective groups transplanted with
SAA-positive cells at 34 wk of age (Fig. 1). Unlike the control
groups, proteinuria in the groups treated with SAA-positive
cells did not worsen significantly from 26 to 34 wk. Renal
function, as estimated from 24-h creatinine clearance, was
significantly better in the ischemic group transplanted with
SAA-positive cells than in the ischemic group transplanted
with SAA-negative cells at 30 and 34 wk of age. Rat creatinine
clearance data are affected by low creatinine production in rats
and serum creatinine levels near detection limits. However,
these results were complemented by histology (as described
below). In addition, kidneys of sham and ischemic rats trans-
planted with SAA-negative cells were larger than kidneys of
rats that received SAA-positive cells (Fig. 1). These large
ischemic/diabetic kidneys from rats transplanted with SAA-
negative cells were very pale and lacked corticomedullary
differentiation, grossly consistent with advanced CKD, i.e.,
with widespread fibrosis and microvascular attenuation (Fig.
1). In marked contrast, the strikingly pallid appearance of
ischemic/diabetic kidneys transplanted with SAA-negative
cells was partly averted by cell transplantation with SAA-
positive cells.
Three fundamental features of renal histology were then
delineated with specific stains, as shown in Fig. 2. Masson’s
trichrome stain showed extensive peritubular fibrosis in sham
rats transplanted with SAA-negative cells, a feature even more
pronounced in ischemic rats transplanted with SAA-negative
cells. In contrast, peritubular or interstitial renal fibrosis was
restricted to very small areas in sham and ischemic rats
transplanted with SAA-positive cells. PAS stain, which was
used to characterize the cellular integrity in tubules and glom-
eruli, revealed significant tubular and glomerular damage, with
profound cellular loss in tubules and glomeruli of sham and
ischemic rats transplanted with SAA-negative cells. Finally,
Leder’s stain exposed large numbers of peritubular neutrophils
in sham and ischemic rats transplanted with SAA-negative
cells, whereas the renal neutrophil number was much lower in
rats transplanted with SAA-positive cells. As in human DN
(13), the structural abnormalities in the SAA-positive groups
may be more severe than the functional impairments. Never-
theless, these three pathological features of DN were dramat-
ically reduced in rats transplanted with SAA-positive cells. In
addition, we found that repeated SAA-positive cell transplants
promoted cell proliferation, or DNA repair, as exemplified by
the higher proportion of tubular nuclei expressing PCNA.
Some, but not all, of the PCNA-positive cells were also GFP
Table 1. Mean weights and serum glucose for each group
Group
Weight, g Glucose, mg/dl
10 wk 16 wk 20 wk 34 wk 10 wk 16 wk 20 wk 34 wk
SA 319 9.2 426  5.5 488 7.9 566  9.8 170  18 173  16 175  15 158  5.5
SB 317 9.2 426  6.8 487 6.1 577  4.2 166  8.1 161  9.7 180  5.9 154  3.2
IA 321 9.5 426  10 479  11 552  17 174  8.8 175  9.0 173  14 150  6.2
IB 311 9.9 427  11 481  11 584  28 174  9.4 169  16 182  10 155  5.1
Lean 314 34 414  10 478  16 530  12 122  7.6 137  5.2 124  3.2 137  1.3
Rats were divided into the following groups: rats subjected to sham operation and that received control, serum amyloid A (SAA)-negative tubular cells (SA
group), rats subjected to sham operation and that received SAA-expressing tubular cells (SB group), rats subjected to renal ischemia and that received control,
SAA-negative tubular cells (IA group), and rats subjected to renal ischemia and that received SAA-expressing tubular cells (IB group). Lean rats were lean,
age-matched male Zucker/SHHF F1 hybrid rats. Mean blood glucose in the diabetic groups (SA, SB, IA, and IB groups) was significantly greater than in lean
animals at each time point.
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positive. In conjunction with the higher rates of tubular cell
proliferation, we found lower rates of renal cell apoptosis
among rats transplanted with SAA-positive cells. These find-
ings were demonstrated weeks after the last cell transplant
(Fig. 3).
Glomerular sclerosis is characteristic in progressive CKD (5,
13), and it was extensive in ischemic/diabetic rats treated with
SAA-negative cells and, although present, was significantly
less in ischemic rats injected with SAA-positive cells. Whereas
glomerular fibrosis was relatively minor in the two sham
groups, the average fraction of glomerular fibrosis was still
lower in sham rats injected with SAA-positive cells than in
sham rats injected with SAA-negative cells. Therefore, trans-
plantation with SAA-positive cells supported tubular and glo-
merular integrity. We deduced from these results that adequate
nutrient delivery to those tissues required a competent micro-
vasculature, specifically the maintenance of vulnerable peritu-
bular capillaries (22). Accordingly, we labeled the renal peri-
tubular microvasculature with an anti-Von Willebrand factor
antibody (26) and evaluated the role of cell transplantation
(Fig. 4). The images shown in Fig. 4 illustrate severe micro-
vascular attenuation in the renal peritubular capillaries of
ischemic/diabetic rats transplanted with SAA-negative cells. In
contrast, this distinctive vascular pathology of progressive
CKD in DN (22) was less in the groups treated with SAA-
positive cells.
We then tested the possibility that sustained donor cell engraft-
ment occurred during the long-term improvements in progressive
CKD by cell transplantation. Four independent methods were
used to identify male donor cells in female recipient kidneys, as
shown in Figs. 5 and 6. FISH with a probe specific to the rat Y
chromosome revealed its unmistakable presence in female recip-
ient kidneys transplanted with male kidney cells, largely in corti-
cal tubules. In addition, the presence of the SRY male determinant
gene was confirmed by PCR in the female recipient kidneys and
not in female kidneys that did not receive male cells (Fig. 5).
Moreover, fluorescence microscopy of recipient kidneys
showed that GFP-expressing donor cells were incorporated
into the tubules, but not in glomeruli, of the host kidneys.
GFP-positive cells were usually found in clusters of “grafted”
tubules (Fig. 5). Furthermore, RT-PCR was used to demon-
strate the expression of SAA mRNA in recipient kidneys. SAA
mRNA was only expressed in the kidneys that received SAA-
positive cells (Fig. 6). Finally, SAA protein expression in
transplanted cells was confirmed by the colocalization of SAA
immunofluorescence and GFP fluorescence only in sham and
ischemic kidneys from rats that received SAA-positive cells
(Fig. 6).
DISCUSSION
There is no effective way to arrest progressive CKD in DN
where vasculopathy (22, 27, 31) and renal ischemia can ad-
vance the progression of CKD toward ESRD (32), constituting
the main problem in nephrology today (24). Once a patient
develops ESRD, renal transplantation is the only effective
means of freedom from dialysis dependency. Unfortunately,
the need for kidneys vastly exceeds availability, and while
kidney transplantation is an excellent option, it is feasible only
in a small minority of dialysis patients (33). Therefore, the
numbers of diabetic CKD and ESRD patients continue to climb
Fig. 1. Effects of renal cell transplantation in diabetic nephropathy. Significant
improvements in proteinuria (g albumin/g creatinine), creatinine clearance (ml/min
10), and kidney weights (mg  2) were seen in 34-wk-old rats that received
serum amyloid A (SAA)-expressing cells at 15 and 20 wk of age (top). Better renal
function was also seen in the SAA-positive postischemia group at 30 wk. Lack of
progressive proteinuria from 26 to 34 wk was seen in the SAA-positive groups.
Kidneys from obese/diabetic rats treated with control cells were pale and avascular
with hemorrhage and fibrosis (visualized with trichrome stain; insets), in contrast
to those from rats given SAA-expressing cells (bottom). Rats were divided into the
following groups: rats subjected to sham operation and that received control, SAA-
negative tubular cells (SA group; n 6 rats), rats subjected to sham operation and that
received SAA-expressing tubular cells (SB group; n 6 rats), rats subjected to renal
ischemia and that received control, SAA-negative tubular cells (IA group; n 7 rats),
and rats subjected to renal ischemia and that received SAA-expressing tubular cells (IB
group; n  9 rats). *P  0.05 vs. the SA group; §P  0.05 vs. the IA group.
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and, with that, the enormous economic cost required for their
care (22a). Accordingly, new tactics are badly needed to limit
the progression of CKD to ESRD in DN. In this report, we
describe the role of IRCT (19) in obese and diabetic rats with
an episode of ischemic acute kidney injury followed by pro-
gressive CKD. We termed this morbid sequence of events the
postischemic inflammatory syndrome and have previously de-
scribed its eventual outcome toward ESRD (12, 14). The
reported ischemic/diabetic rat nephropathy model was de-
signed to mimic progressive CKD from DN, a condition driven
by subclinical episodes of renal ischemia and tubular necrosis
(13). Cell transplants were performed on obese/diabetic rats
with severe and progressive CKD at 15 and 20 wk of age, and
rats were then followed for 14 wk more, to 34 wk of age. There
were no attempts to modify dietary or metabolic factors on any
of the groups. IRCT was performed with normal adult male ZS
rat renal tubular cells reprogrammed to express a murine
isoform of SAA1 (15) before transplantation. These repro-
grammed primary renal cells grow out of harvested renal
tubules transfected with the SAA gene and, after 1 wk, form de
novo tubules in vitro, the basic structure of renal epithelial
redifferentiation and a presumed requirement for their regen-
erative supporting effects (15, 16). SAA expression was chosen
to reprogram and redifferentiate cultured renal cells because of
its strong tubulogenic property (15), an idea supported by our
current and previous work (15, 16, 19). For example, we found
that even poorly differentiated rat NRK52E cells dramatically
improved renal function in multiple models of acute kidney
injury only when these cells expressed SAA (16). In these
studies, no effect was seen in the absence of renal failure (16).
The original experiments with SAA-positive and SAA-nega-
tive NRK52E cells were followed by successful transplantation
Fig. 2. Effects of renal cell transplantation on renal histology. Decreased fibrosis (blue, top), tubular atrophy (middle), and neutrophil infiltration (red cells,
bottom) were observed in obese/diabetic rats treated with SAA-expressing cells both after sham surgery or renal ischemia. Representative trichrome-stained
sections of cortex (top) as well as periodic acid-Schiff (PAS)-stained (middle) and Leder-stained (bottom) sections are included. The quantification of 200
microscope fields/group is shown in the graphs. For interstitial fibrosis, n  85 for the SA group, 92 for the SB group, 63 for the IA group, and 92 for the IB
group. For atrophic tubules, n  85 for the SA group, 92 for the SB group, 63 for the IA group, and 92 for the IB group. For neutrophil number, n  45 for
the SA group, 45 for the SB group, 79 for the IA group, and 47 for the IB group. Scale bar  50 m. *P  0.05 vs. SA; §P  0.05 vs. IA.
Fig. 3. Effects of renal cell transplantation on cell
proliferation. Significantly higher expression of
proliferating cell nuclear antigen (PCNA) and
less apoptosis were seen in kidneys from rats that
received SAA-expressing (vs. control) cells.
A: representative images stained with anti-PCNA,
Texas red secondary antibody, and 4=,6-di-
amidino-2-phenylindole to label all nuclei. B and
C: quantification of PCNA-positive (B) and ap-
optotic (C) nuclei. Forty-three images were eval-
uated. *P  0.05 vs. SA; §P  0.05 vs. IA.
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experiments with primary renal epithelial cells (19). In these
experiments, renal tubular cells were harvested from a rat
donor with advanced CKD, reprogrammed and expanded ex
vivo, and then given back to the donor. SAA-positive renal
cells reversed the donor CKD when auto-transplanted intrave-
nously (19). In addition, improvements in renal function and
histological injury and expression of SAA1 were seen in
nondiabetic postischemic animals (19).
We now report on another advancement derived from our
earlier cell transplant work: the long-term prevention of pro-
gressive CKD in diabetes and ischemia by transplanted renal
cells. We achieved near-complete renal protection with IRCT
Fig. 4. Effects of renal cell transplantation on glomerulosclerosis and vascular density. Significantly decreased glomerulosclerosis and improved microvascular
density were observed in rats that received SAA-expressing cell transplants. Glomerulosclerosis was evaluated in trichrome-stained sections and vascular density
by immunostaining with anti-von Willebrand factor antibody. Quantification is shown in the graphs. For numbers of glomeruli/group measured, n  1,054 for
the SA group, 888 for the SB group, 1,050 for the IA group, and 1,363 for the IB group. For numbers of 200 microscope fields/group, n  8 for the SA group,
15 for the SB group, 32 for the IA group, and 16 for the IB group. Scale bar  50 m. *P  0.05 vs. SA; §P  0.05 vs. IA.
Fig. 5. Male tubular cell engraftment in female kidneys. Engraftment of infused cells is shown via fluorescence in situ hybridization (FISH; red) for the Y
chromosome. Merged fluorescence and bright images show FISH-positive cells from male donors in tubules of female kidneys 14 wk after the final cytotherapy
treatment (age: 34 wk) as well as in normal males but not in female kidneys (insets show the areas at the arrows). Double arrows show tubular basement
membranes. In addition, specific DNA encoding the male determinant gene sex-determining region on the Y chromosome (SRY) was found in female kidneys
that received male tubular cells but not in female kidneys that did not receive cells (negative control). The positive controls correspond to DNA extracted from
the normal liver of male Sprague-Dawley rats. Mean band density for the SRY PCR is presented in top graph. Right: GFP-positive cells within kidneys of rats
treated with control (A) or SAA-positive (B) cells with quantification of GFP-positive cells in a total of 212 high-power fields (hpf). In contrast, GFP-positive
cells were 1 cells/hpf in kidneys of normal rats without renal injury (16). GFP-positive cells were very rarely seen in other organs (Table 2). MW, molecular
weight marker; 	A, 	-actin (to insure the equivalent DNA substrate for PCR). *P  0.05 vs. SA; §P  0.05 vs. IA.
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using SAA-expressing primary adult renal cells. These results
corroborate the great potential of primary renal cell transplants
in devastating clinical situations. The two sequential cell trans-
plants were given to rats with severe chronic renal injury from
diabetes and ischemia (12, 14). We then followed the progres-
sion of CKD until obese/diabetic rats were 34 wk of age and
found that cell transplants, given at 15 and 20 wk of age,
dramatically prevented the renal damage caused by diabetes
and by added renal ischemia sustained at 10 wk of age.
Moreover, higher rates of renal tubular cell proliferation and
lower rates of cell apoptosis were observed 14 wk after the last
transplant with SAA-positive cells. In contrast, at this late
stage, posttransplant glomerular proliferation and apoptosis
were not detected. Furthermore, at termination, we verified that
male SAA-expressing renal cells were still present in recipient
kidneys 19 and 14 wk after the two cell transplants, respec-
tively. In a previous study (16), colocalization of transporters
(organic anion transporter 1 and Na/H exchanger 3) with
GFP was found in kidneys from rats treated with SAA-positive
cells, suggesting that the engrafted cells are functional. We
assume that persistent engraftment of donor cells was respon-
sible for the long-standing renal protection, although we do not
know how donor renal cells limited nephropathy. While find-
ing aggregate distributions of donor cells suggested replication
in host kidneys, the transplanted cells could only represent a
minority of the final and total tubular cell mass. Moreover, it is
very unlikely that adult donor epithelial cells acted as progen-
itors, capable of regenerating damaged microvascular networks
or glomeruli. We suggest that anchored donor tubular cells
positively influenced (via paracrine or endocrine signaling)
recipient renal cells to repopulate the injured kidney. In a
previous study (16) in other models of renal failure, we have
found increased expression of PCNA in kidneys from rats that
received SAA-positive cells compared with control cells. In
addition, the transplanted cells may have (e.g., via secreted
VEGF (19)] attracted renal cell endothelial precursors, circu-
lating cells that are thought to contribute to restoration of
vascular function after injury (3). Better microvascular func-
tion (Fig. 4) results in better local renal perfusion and the
delivery of O2 and nutrients, and this has been postulated to
result in less tissue injury and inflammation (Fig. 2) as well as
better function (Fig. 1). The mechanism of renal regeneration
is at the forefront of cell therapy, and previous designs were
Fig. 6. SAA expression in recipient kidneys. The presence of recipient kidney SAA mRNA was detected by RT-PCR. Quantification of band density in multiple
blots is shown in the graph. SAA mRNA was found in kidneys after reprogrammed cell infusions, demonstrating transcriptional activity. The representative
fluorescence images show nuclei (blue), immunoreactive SAA (red), and GFP-positive cells (green) in each group [including normal controls (C) without renal
injury]. In the right images, images of nuclei, SAA, and GFP are merged to demonstrate colocalization (orange) of SAA and GFP in SB and IB groups, consistent
with expression in the same cells. Scale bar  50 m. *P  0.05 vs. SA; §P  0.05 vs. IA.
Table 2. Mean number of green fluorescent protein-positive
cells by organ removed at 34 wk
Group Lung Liver Spleen
SA 0.06  0.04 0.14 0.04 0.20  0.14
SB 0.14  0.08 0.09 0.09 0.05  0.05
IA 0.09  0.05 0.04 0.04 0.07  0.07
IB 0.11  0.08 0.07 0.05 0.13  0.10
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focused on attempts to replace diverse cell populations of the
injured kidney with pluripotent cells (2, 4, 7, 11, 29). However,
progenitor cells do not become functional renal cells and do not
restore a normal renal phenotype (6). What is more, in some
cases, transplanted stem cells may even acquire a totally
undesirable and uncontrolled phenotype in recipient kidneys
with CKD (20). Our results indicate that in progressive CKD
from DN, improved renal function and structure, inclusive of
glomeruli, tubules, and microvessels, can be accomplished by
SAA-positive renal cell transplants, a discovery that addresses
the conundrum of trying to replace exceedingly diverse com-
plex cell groups (8). In other words, tubular cell transplants
positively affect most, if not all, renal cell types in the recip-
ient. The broad benefit of cell transplants points to a general
action that can be best explained by an improved vasculature
with better delivery of O2/nutrients. Furthermore, this vascular
hypothesis is also supported by our comprehensive genomic
analysis of DN, which showed that renal ischemia was the
driving force behind most alterations to the renal transcrip-
tomes in DN (17). There have been reports of stem cell therapy
in various models of CKD. However, unequivocal evidence of
stem cell differentiation is lacking, and there is no real consis-
tency in the effects among various groups (1). In conclusion,
we propose that in CKD, adult renal epithelial cells offer a
physiological and effective means to effect the preservation of
renal function.
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